Background and Aims: Due to the mechanism of non-small cell
lung cancer (NSCLC) treatment failure directs of the next step of management, rebiopsy in patients with NSCLC resistant to systemic chemotherapy or tyrosine-kinase inhibitors (TKI) became important. However, getting adequate rebiopsy sample for gene-mutation or other examination is difficult. We present a case who received Guiding device as assisted tool with endobronchial ultrasound transbronchial biopsy (EBUS-TBB) to get adequate rebiopsy sample.
Our case is a 64 y/o male patient with NSCLC, adenocarcinoma, diagnosed 4 years ago. The initial diagnosis was based on pathologic result from surgical sample from spinal metastasis. He received erlotinib and osimertinib treatment previously. Rebiopsy via EBUS-TBB was performed ever about 6 months before. However, the result of rebiopsy showed chronic inflammation and focal micro-calcification only. The current treatment regimen was pemetrexed with bevacizumab. However, the followed chest computed tomography showed disease progression again.
Methods:
We used EBUS-TBB with Guide sheath (BF-1TQ290/ EU-ME2/ Guide sheath K203, Olympus, Tokyo, Japan) to perform rebiopsy at the same site 6 months before. This time, we combined with Guiding device (Guiding device, Olympus, Tokyo, Japan) as assisted tool.
Results: Within type peribronchial lesion, less than 1 cm, was noted at RB10. It was difficult to get sample while performing biopsy directly. After using Guiding device to dig at the lesion site, we got 6 pieces sample successfully. The final report of pathology was adenocarcinoma, with EGFR mutation (c.2573T>G; c.2369C>T). There was no ALK expression and negative PD-L1 expression. Background and Aims: The diagnosis of peribronchial pulmonary lesions located in the tertiary bronchi, also known as segmental bronchi, as well as, the 4th order and 5th order segmental bronchi is very difficult. Histopathological specimens cannot be easily obtained by endobronchial biopsies (EBBX) due to the patent but small segmental bronchial lumen. The aim of our study was to evaluate the diagnostic accuracy and safety of the novel technique with radial probe endobronchial ultrasound (R-EBUS) assisted conventional transbronchial needle aspiration(C-TBNA)in the diagnosis of solitary peribronchial pulmonary lesions located in segmental bronchi from 3th to 5th order.
Methods: From December 2014 to December 2015, 16 patients with computed tomography-confirmed solitary peribronchial pulmonary lesions located in segmental bronchi from 3th to 5th order were enrolled. The lesions were first located using radial probe endobronchial ultrasound to determine sites of conventional transbronchial needle aspiration, then, histopathological specimens were obtained using the technique of C-TBNA, and a final pathological diagnosis was made based on the findings from surgical specimens. Statistical analyses were performed for specimen results and complications.
Results: On pathological evaluation, 14 of the 16 specimens were malignant, including 8 adenocarcinomas, 4 squamous cell carcinomas, and 2 small cell carcinomas, while 2 were non-malignant diseases. The diagnostic accuracy rate, sensitivity and missed diagnosis rates were 87.5%, 87.5% and 12.5%, respectively. Combining the results of cytology and histologic samples obtained from C-TBNA the total diagnostic accuracy rate, sensitivity and missed diagnosis rate were 93.75%, 93.75% and 6.25%, respectively. There were 2 cases of bleeding complications >5 mL after C-TBNA, and both resolved with endobronchial management.
Conclusion:
The combination of R-EBUS with C-TBNA was advantageous and safe for the diagnosis of solitary peribronchial pulmonary lesions located in the segmental bronchi. However, possible bleeding complications should be anticipated with needle aspiration. Further verification of this combined application should be investigated in larger clinical trials.
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